Results 91 to 100 of about 11,332,305 (264)

Longitudinal Awake Mouse Brain Imaging Using Functional Ultrasound and Functional Ultrasound Localization Microscopy

open access: yesAdvanced Science, EarlyView.
Awake longitudinal multimodal ultrasound imaging integrates functional ultrasound (fUS), ultrasound localization microscopy (ULM), and functional ULM (fULM) to characterize cerebrovascular function, microvascular architecture, and flow dynamics within the same animals over time.
Zhe Huang   +9 more
wiley   +1 more source

Regional distribution of amyloid-Bri deposition and its association with neurofibrillary degeneration in familial British dementia [PDF]

open access: yes, 2001
Familial British dementia (FBD), pathologically characterized by cerebral amyloid angiopathy (CAA), amyloid plaques, and neurofibrillary degeneration, is associated with a stop codon mutation in the BRI gene resulting in the production of an ...
Tammaryn Lashley   +44 more
core   +1 more source

Lipid Metabolic Dysregulation Driven by OSMR Mutations Underlies Amyloidogenesis in Primary Localized Cutaneous Amyloidosis

open access: yesAdvanced Science, EarlyView.
OSMR mutations disrupt STAT5 signaling and AKR1B10‐mediated lipid metabolism, leading to lipid accumulation and protein aggregation in keratinocytes. This metabolic reprogramming drives amyloid deposition in primary localized cutaneous amyloidosis, revealing a mechanistic link between lipid dysregulation and amyloidogenesis.
Huiting Liu   +8 more
wiley   +1 more source

Amyloid-Related Imaging Abnormalities Associated With Immunotherapy In Alzheimer‘s Disease Patients

open access: yesFuture Neurology, 2012
Evaluation of: Sperling R, Salloway S, Brooks DJ et al. Amyloid-related imaging abnormalities in patients with Alzheimer’s disease treated with bapineuzumab: a retrospective analysis. Lancet Neurol. 11(3), 241–249 (2012). Amyloid-related imaging abnormalities (ARIAs) have been reported in patients with Alzheimer’s disease treated with bapineuzumab, a ...
Panza, F.   +6 more
openaire   +1 more source

Decoding Biomolecular Phase Separation: From Physiological Roles to Pathological Mechanisms and Therapeutic Biomaterials Design

open access: yesAdvanced Science, EarlyView.
This review systematically elaborates on the mechanisms underlying physiological regulation and pathological dysregulation of biomolecular phase separation. It also summarizes advances in phase‑separation‑targeted therapeutic strategies and the design of functional biomaterials inspired by this process.
Jiawei Zhu   +5 more
wiley   +1 more source

Bacteria‐Derived 1‐Allylpiperazine Alleviates Symptoms of Parkinson's Disease Model by Promoting Autophagy

open access: yesAdvanced Science, EarlyView.
Parkinson's disease currently has no disease‐modifying therapies. In Caenorhabditis elegans, Escherichia coli E8 alleviates α‐synuclein‐provoked PD‐related defects through its bioactive metabolite 1‐ALPP, which combats PD by triggering AMPK/mTOR/HLH‐30‐dependent autophagy and suppressing α‐synuclein LLPS‐mediated fibrillization.
Mingqin Qu   +12 more
wiley   +1 more source

Cerebral Amyloid Angiopathy: Clinical Presentation, Sequelae and Neuroimaging Features—An Update

open access: yesBiomedicines
The prevalence of cerebral amyloid angiopathy (CAA) has been shown to increase with age, with rates reported to be around 50–60% in individuals over 80 years old who have cognitive impairment. The disease often presents as spontaneous lobar intracerebral
Stefan Weidauer, Elke Hattingen
doaj   +1 more source

Cross‐Organ Multi‐Omics Profiling of Systemic Alterations in 5xFAD Mice and Changes Associated with Huanglian Jiedu Decoction Treatment

open access: yesAdvanced Science, EarlyView.
Cross‐organ multi‐omics reveals coordinated inflammatory and metabolic disturbances in 5xFAD mice. Huanglian Jiedu Decoction improves cognition and alleviates brain and liver abnormalities. Complementary hepatocyte–microglia conditioned‐medium experiments suggest PPAR‐γ involvement in treatment‐associated changes in microglial inflammation, providing ...
Wenya Gao   +10 more
wiley   +1 more source

Real‐world experience with lecanemab therapy for Alzheimer's disease in the Intermountain West

open access: yesAlzheimer’s & Dementia: Diagnosis, Assessment & Disease Monitoring
INTRODUCTION Lecanemab is a monoclonal antibody targeting amyloid plaques that has been approved for the treatment of early symptomatic Alzheimer's disease.
Bethany C. Curd   +8 more
doaj   +1 more source

From Lesion to Decision: AI for ARIA Detection and Predictive Imaging in Alzheimer’s Disease

open access: yesBiomedicines
Background: Alzheimer’s disease (AD) remains the leading cause of dementia worldwide, with anti-amyloid monoclonal antibodies (MABs) marking a significant advance as the first disease-modifying therapies. Their use, however, is limited by amyloid-related
Rafail C. Christodoulou   +11 more
doaj   +1 more source

Home - About - Disclaimer - Privacy